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Abstract
The objective 1 of this study was to investigate trends in breast
cancer (BC) prediction using machine learning (ML) publications
by analysing country, first author, journal, institutional collabora-
tions and co-occurrence of author keywords. The objective 2 was
to provide a review of studies on BC prediction using ML and a
blood analysis dataset (Breast Cancer Coimbra Dataset [BCCD]),
and the objective 3 was to provide a brief review of studies based
on BC prediction using ML and patients’ fine needle aspirate
cytology data (Wisconsin Breast Cancer Dataset [WBCD]). The
design of this study was as follows: for objective 1: bibliometric
analysis, data source PubMed (2015-2019); for objective 2: sys-
tematic review, data source: Google and Google Scholar (2018-
2019); for objective 3: systematic review, data source: Google
Scholar (2016-2019). The inclusion criteria for objective 1 were
all publication results yielded from the searches. All English
papers that had a ‘PDF’ option from the search results were
included for objective 2. A sample of the ‘PDF’ English papers
were included for objective 3. All 116 female patients from the
BCCD, consisting of 64 positive BC patients and 52 controls were
included in the study for objective 2. For the WBCD, all 699
female patients comprising of 458 with a benign BC tumour and
241 with a malignant BC tumour were included for objective 3.
All 2928 publications were included for objective 1. The results
showed that the United States of America (USA) produced the
highest number of publications (n=803). In total, 2419 first
authors contributed towards the publications. Breast Cancer
Research and Treatment was the highest ranked journal.
Institutional collaborations mainly occurred within the USA. The
use of ML for BC screening and detection was the most
researched topic. A total of 19 distinct papers were included for
objectives 2 and 3. The findings from these studies were never
presented to clinicians for validations. In conclusion, the use of
ML for BC screening and detection is promising.
Introduction
Breast cancer
Brief overview of breast cancer
Breast cancer (BC) is a global terminal disease that has always
been known for its high prevalence in both incidence and mortal-
ity rates. Due to BC’s complex nature, there is still no cure, despite
ongoing attempts worldwide.1 Similarly, the precise cause of BC
remains unclear, although researchers have, to date, identified
potential risk factors, such as: i) gender; ii) aging; iii) gene muta-
tions; iv) family history; and v) unhealthy lifestyles.2 The manage-
ment of the disease is dependent on treatment by clinicians. To this
end, the early identification of BC (through BC screening and
detection methods) is important so that the disease is identified
during its initial stages when malignant cells are local to the
breast(s) only. If not caught early, the malignant BC cells spread
to other parts of the body and patients are often subjected to much
more complex, invasive treatments. Patients with late diagnosis
often have lower survival rates and may die soon after being diag-
nosed.
Traditional global breast cancer screening methods
Developing and developed countries utilize different mediums
for BC screening, depending on resource availability. Developing
countries commonly rely on breast self-examination (BSE) and
clinical breast examination (CBE) for BC screening.3 On the other
hand, developed countries often use mammography for the same
purpose.4
Traditional global breast cancer detection methods
The triple assessment test is termed the ‘gold standard’ for BC
detection and is traditionally used worldwide. A combination of
three tests together form the triple assessment test: CBE, radiolog-
Systematic Reviews and Meta-Analysis 
Significance for public health
This is the first study to perform a snapshot of a bibliometric analysis on the topic of breast cancer (BC) prediction using machine learning (ML) by analysing
publications from an online electronic database. This is also the first systematic review on studies that have focused on BC prediction using ML and a blood
analysis dataset, specifically, the new publicly available Breast Cancer Coimbra Dataset (BCCD) which has the potential in identifying more efficient and
cheap BC biomarkers and ML models. Additionally, we conducted a brief systematic review of studies focused on BC prediction using ML and a publicly avail-
able fine needle aspirate cytology dataset called the Wisconsin Breast Cancer Dataset (WBCD), which may also discover BC biomarkers. It is evident that the
use of ML for BC screening, detection and identification of potential BC biomarkers is promising, however, these results need to be showcased to clinicians for
validations.
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ical imaging (mammography and/ or ultrasonography) and pathol-
ogy (fine needle aspirate cytology [FNAC] or core needle
biopsy).5 A patient is positively diagnosed with BC if at least one
of these three tests indicate malignancy and the result is negative
for BC if all three tests indicate a benign breast condition.5
Despite the use of the aforementioned methods in identifying
BC, both global incidence and mortality rates remain high. A
recent comprehensive global cancer study by the Global Burden of
Disease Cancer Collaboration reported BC as third (1.7 million
incidents and 535,000 deaths) in the global top ten highest cancer
incidences in 2016.6 The majority of these BC incidents and deaths
were among women.6 In addition, traditional methods of identify-
ing diseases such as BC in medicine is based on a linear approach
called regression.7,8 Regression assumes that the BC risk factors
are linearly related.9 However, these risk factors are usually not
linearly related and regression methods may therefore be unreli-
able.9 The machine learning approach does not assume linearity
and may form an alternative basis for more efficient BC identifica-
tion methods.   
Machine learning
What is machine learning?
Machine learning (ML) is used to program computers to iden-
tify patterns from data in different domains by the creation of
mathematical models.10 Although ML has been in existence since
the 1950s, the field is currently growing at an exponential rate
worldwide.11 The reason for this rapid growth is due to a similar
trend in the vast creation of data and massive computing power.11
At present, ML is widely employed in domains such as banking,
education, government, agriculture and medicine. There are two
main categories of ML: supervised learning and unsupervised
learning.12 Under supervised learning, ‘classification’ is a promi-
nent sub-category widely employed in the medical domain, and is
the focus of the review portion of this paper.  
Similitude of the machine learning classification process to the
human life cycle
The ML classification process can be likened to the human life
cycle. In this cycle, a male and female (parents) produce a child.
Once the child is born, as he or she grows, the parents teach the
child various things. For example, the child is pointed to an apple
and learns, ‘this is a fruit’. When the child sees a different apple, if
he or she is able to identify the apple as a fruit, the child would
have learnt well. Otherwise, the child would fail to identify the
new apple. 
An overview of the machine learning classification process
Similarly, during the ML classification process, a model (child)
is built using an algorithm (parents). There are many different
algorithms, such as the famous Logistic Regression (LR). Models
can be built using a single algorithm or a combination of algo-
rithms (ensemble). Models are trained using a portion of data,
called the ‘training set’, for example BC data (this can be likened
to how the parents teach a child to identify apples). Then, the
model is tested on unfamiliar data (‘test set’) for the same concept
(the child is presented with a new apple to classify). If the model
is able to accurately identify the concept, such as ‘BC tumour pre-
sent’, then the model is said to be good and robust. Otherwise, the
model is poor and will require more training.
Using machine learning for breast cancer prediction
Importance of BC prediction using ML for BC screening and
detection
Patient data obtained from BC screening or detection methods
may be used to create ML models for predicting BC. An example
of this data are results from FNAC tests. However, finding a
cheaper and more efficient set of BC data predictors such as results
from patients’ routine anthropometric blood tests would be a better
approach. If a model consistently performs well using this blood
data, the model can be used to build an Artificial Intelligence (AI)
tool. After rigorous testing, the tool may be presented to the Food
and Drug Administration (FDA) for assessment. After the tool
gains FDA approval, the tool may be used by clinicians in clinical
settings to identify BC in patients. The clinicians would input a
patient’s blood result data into the tool and the tool would output
the likelihood of a patient having BC. This would be a more effi-
cient process and a potential first-step for screening and detecting
BC in patients compared to the fairly inefficient, invasive and
expensive traditional methods that patients are first subjected to. 
Research trends in the BC prediction using ML field
A considerable amount of literature has been published on applica-
tions of BC prediction using ML. However, it is difficult to keep track
of the span of knowledge generated in terms of publication trends in
this field. Bibliometric analysis is a tool generally used in the biomed-
ical sciences to statistically analyse biomedical literature from online
databases such as PubMed for assessment of research trends. For
instance, bibliometric analyses have been published on cancer,13 tuber-
culosis14 and public health.15,16 However, to our knowledge, there has
been no bibliometric analysis study focused specifically on the BC pre-
diction using ML field. By conducting a bibliometric analysis, it is pos-
sible to examine trends in countries of publications, first authors, jour-
nals, institutional collaborations and co-occurrence of author key-
words. This would provide insight and aid researchers in conducting
future research within this field. 
Context of this paper
The publicly available Wisconsin BC Dataset (WBCD), based
on patients’ FNAC biopsy test results, is most popularly used by
researchers in studies focused on BC prediction using ML, since
this dataset became available online in the 1990s.17,18 Previous
work by Yue et al.,19 which reviewed studies on BC prediction
using ML over a number of years, up to 2017, focused on the
WBCD and only four ML algorithms. Since it was resource inten-
sive to perform FNAC biopsy tests on patients to obtain this data,
a cheaper and more efficient method was required to obtain a set
of patients’ BC data predictors. 
Since Yue et al.’s work,19 the new BC Coimbra Dataset
(BCCD), containing patients’ routine anthropometric blood analy-
sis data to distinguish between patients who were positive or neg-
ative for BC, was uploaded online by Patrício et al.20 There has
since been a growing number of studies published focused on
using the BCCD and ML for BC prediction. 
i. To investigate the five-year (2015-2019) global trend of publi-
cations (analysis of country, first author, journal, institutional
collaborations and co-occurrence of author keywords) from the
PubMed database focused on BC prediction using ML;
ii. To review BC prediction studies focused on ML and the blood
analysis BCCD since its inception, from 2018 to 2019; and 
iii. To provide a brief overview of ML and WBCD studies from
2016 to 2019. For years 2016 and 2017, we review studies not
covered in Yue et al.’s19 work.  









To the best of our knowledge, this is the first work on a biblio-
metric analysis of BC prediction using ML publications. To our
knowledge, this is also the first work providing insight on studies
that have explored the efficacy of using blood analysis data and
ML for BC prediction. This is because the BCCD is so new. Some
BC and ML concepts and terminologies are briefly tabulated in
online supplementary Table 1. 
Methods
Search strategy and study selection 
This systematic review was conducted in accordance with
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) 2009 Statement.21 The search strategies
and study selection for the three objectives are provided below. 
For objective 1 
PubMed searches were performed in October 2019 using the
following settings: all publications sorted by most recent and
publication dates set to five years for the human species and all
article types. An alternative to PubMed is the online Scopus22 or
Web of Science23 databases. However, these were not chosen
because of the costs associated with gaining access to these
databases. In contrast, the bibliometric data in PubMed is freely
accessible. 
Analysis by country
For analysis of country, a list of countries throughout the
world (n=195) was first created in Microsoft Excel® based on
rankings by most populous (https://www.worldometers.info/
geography/how-many-countries-are-there-in-the-world/). An
example of a country search query for China (affiliation filter) is
provided in Supplementary Table 2. Five different synonyms for
the term ‘Breast Cancer’ and 15 synonyms for the term
‘Machine Learning’ (inclusive of names of common ML algo-
rithms) were used, joined with the ‘AND’ keyword. In total,
PubMed would have therefore searched for a total of (1 x 5 x 15)
= 75 combinations in the contents of its publications. The num-
ber of publications were then sorted, and the top ten countries
with the most publications were selected. 
Analysis by first author and journal
For analysis of first author and journal, respectively, the key-
words for the database search are depicted in Supplementary
Table 3. The keywords for this search are similar to that of
Supplementary Table 2, but with the affiliation filter removed. A
Comma-Separated Values (CSV) file was then generated from
PubMed, with an export of the results yield from the above
search. Analysis was performed by first loading the data from
the CSV file into a similarly structured table created in a
MySQL database, followed by programmatic computations
based on the total number of publications by first author and
journal, respectively. The results were sorted and the top ten first
authors and journals were finally selected.
Analysis of institutional collaborations and co-occur-
rence of author keywords
For analysis of institutional collaborations and co-occur-
rence of author keywords, the MEDLINE file from PubMed was
exported with the results yield from the database search shown
in online Supplementary Table 3. The MEDLINE file was used
as input into a computer program called VOSviewer
(https://www.vosviewer.com/)24 to visually analyse the literature
by institutional collaborations and co-occurrence of author key-
words. The MEDLINE file was used because it is the only sup-
ported input file for PubMed in VOSviewer. In this study, net-
work nodes in the visuals produced from VOSviewer represent
institutions or author keywords. 
For objective 2 
A search was performed on Google with the text-word
search terms “breast cancer Coimbra” in September 2019. This
search strategy was employed because it provided access to
papers published on patients’ blood analysis data for BC predic-
tion using ML. The study by Patrício et al.20 was included as a
primary study for this dataset. Thereafter, the “Cited by…” web-
site link on the primary study was clicked. This took us to
Google Scholar, where all papers that had referenced the prima-
ry study, were listed. We included all papers that had a down-
loadable ‘PDF’ option on the right-hand side, alongside the
respective paper listing, during the time of the search. Only
papers published in English were reviewed. In the attempt to
include all English papers, there were two papers that were not
freely available online and ZS purchased these and included
them. These papers were by Hung et al.25 and Singh.26 Finally,
although Polat’s and Senturk’s27 and Akben’s28 papers did not
have a ‘PDF’ option, we consulted with a senior librarian who
was able to provide us with access to these two papers and these
were included in this study. 
For objective 3
The text-word search terms “breast cancer prediction using
machine learning and wisconsin breast cancer data” was used to
search Google Scholar in September 2019. This search strategy
was chosen because it provided access to papers published based
on patients’ FNAC biopsy test result data for BC prediction
using ML. For the years 2016 and 2017, the ‘Custom Range’
option was clicked on the left-hand side and the ‘from’ and ‘to’
textboxes for the respective year were completed. The ‘Search’
button was then clicked. For the years 2018 and 2019, the ‘Since
<year>’ link was clicked, which is located above the ‘Custom
range’ option. In both instances, the sort order was set to ‘Sort
by relevance’. Starting from the top of the list of papers returned
by Google Scholar for the search, if a paper had a downloadable
‘PDF’ option next to it, we read through the paper briefly to ver-
ify that the WBCD was the focus of the study and that ML clas-
sification was the paradigm used. Only papers published in
English were reviewed. Furthermore, for 2016 and 2017 papers,
we cross-checked against Yue et al.’s19 review and excluded any
papers that were already mentioned there, so as to avoid dupli-
cation.  
Finally, for both objectives 2 and 3, Google and/or Google
Scholar were used for the search because of the higher likeli-
hood of gaining access to the full papers in PDF format, as com-
pared to, for example, PubMed. 
Data source
For objective 2 
Breast cancer Coimbra dataset
This publicly available anthropometric blood analysis data
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was created by Patrício et al.20 at the Faculty of Medicine of the
University of Coimbra and uploaded online in 2018. The data
comprises 116 patients, of which 64 (55%) were positively diag-
nosed with BC and 52 (45%) without BC (the controls). There
are nine clinical independent features: Age (years), BMI
(kg/m2), Glucose (mg/dL), Insulin (µU/mL), Homeostasis
Model Assessment (HOMA), Leptin (ng/mL), Adiponectin
(µg/mL), Resistin (ng/mL) and Chemokine Monocyte
Chemoattractant Protein 1 (MCP-1) (pg/dL). The dependant fea-
ture has two classes: ‘BC tumour present’ (value equals ‘2’) and
‘BC tumour absent’ (value equals ‘1’). There are no missing data
in the BCCD. The BCCD is available at: https://archive.ics.uci.
edu/ml/datasets/Breast+Cancer+Coimbra and details of this
dataset can be found in Patrício et al.20
For objective 3 
Wisconsin breast cancer diagnosis dataset 
The Wisconsin Breast Cancer Dataset (WBCD) consists of
nuclear features of FNAC biopsy test result data taken from
patients’ breasts, and was created by Dr William H. Wolberg18 at
the University of Wisconsin Hospitals and made available online
in 1992. The dataset contains records collected from 699
patients of which 458 (65.5%) were from patients who had a
benign BC tumour and 241 (34.5%) cases were from patients
with a malignant BC tumour. The nine independent features are:
Clump Thickness, Uniformity of Cell Size, Uniformity of Cell
Shape, Marginal Adhesion, Single Epithelial Cell Size, Bare
Nuclei, Bland Chromatin, Normal Nucleoli and Mitoses. All
nine features have values in the range between 1 to 10, where 1
represents a normal state and 10 represents a most abnormal
state. The dependant Diagnosis feature has either a value of 4 or
2, where 4 denotes malignant BC tumour diagnosis and 2
denotes benign BC tumour diagnosis. From the 699 records, 16
records have missing values for the ‘Bare Nuclei’ feature. The
WBCD is available at: https://archive.ics.uci.edu/ml/datasets/
Breast+Cancer+Wisconsin+%28Original%29.
Summary measures
For objectives 2 and 3
After a ML model is trained, it is tested using an unfamiliar
portion of a dataset, called the ‘test set’. The Confusion Matrix
(CM) table is used for evaluation of this model’s performance.
In the case of both the BCCD and the WBCD, since there are
two classes for these datasets, respectively, the CM forms a two-
by-two table, showing total actual versus predicted values per
class. True Positive (TP) and True Negative (TN) are the correct
predictions made by a model. False Negative (FN) and False
Positive (FP) are the incorrect predictions made by a model. The
TP value is located in row 1, column 1 of the CM and FN is
located in row 1, column 2 of the CM. The FP value is located
in row 2, column 1 of the CM and TN is located in row 2, col-
umn 2 of the CM. 
Using the CM, the following metrics are traditionally used to
evaluate model performances in ML studies: i) accuracy; ii) pre-
cision; iii) recall or sensitivity; iv) specificity; v) F1 score; vi)
Receiver Operating Characteristics (ROC) curve; and vii) Area
Under the ROC Curve (AUC). Calculations for these are provid-
ed in eqs. (1)-(5).29,30
The F1 score is known as the harmonic mean of recall and pre-
cision.10 The ROC curve is a two-dimensional graph showing one
minus specificity on the  axis and sensitivity on the  axis.10 The
AUC is obtained from the whole area under the ROC curve and
shows performances of both classes of a model. Finally, for all the
aforementioned metrics, the highest value is one, meaning 100%
or best performance and the lowest value is zero. 
Patient and public involvement 




For objective 1 
For the analysis by country, results were found for 86 of the
195 countries. The results were sorted from highest to lowest
according to the total number of publications. The top ten countries
were selected based on the highest total number of publications. 
For the analysis by first author, journal, institutional collabora-
tions and co-occurrence of author keywords, 2928 records were
returned from the search, of which there were approximately 2419
distinct first authors and 670 distinct journals. The top ten first
authors and journals were selected after computations of the total
number of publications and sorting these from highest to lowest.
The VOSviewer computer program found 10100 distinct institu-
tions from the MEDLINE file. Of these 10100 institutions, institu-
tional collaborations were found for nine and these were included
in this category’s analysis. The VOSviewer computer program
identified 4755 different author keywords in the MEDLINE file, of
which 123 were found to have co-occurrence by author keywords
and were included in this analysis. 
For objective 2 
The results presented following the PRISMA flow diagram
(Figure 1)21 depicts the search process and study selection.
Primary searches of Google and Google Scholar yielded 16 poten-
tially relevant papers. Since there were no duplicates, the 16 papers
were screened. After reading the titles and abstracts of these 16
papers, two papers were excluded for the following respective rea-
sons: i) the study did not use the blood analysis BCCD and Patrício
et al.’s20 study was instead referenced to explain a ML algorithm;
and ii) Patrício et al.’s20 study was referenced for experimental
results and not to actually create any ML classification models
based on the BCCD. The full texts of the remaining 14 papers were
reviewed and another three excluded for any of the following rea-










sons: i) the study did not use ML classification and instead used
semi-supervised ML; ii) Patrício et al.’s20 study was referenced
under related work and the BCCD was not used for model creation;
iii) models were created using statistics and not ML classification.
Therefore, 11 eligible studies were ultimately included.20,25-28,30-35
For objective 3
For years 2016 to 2017, Google Scholar yielded 6130 potential
papers. Starting from the first page of the results, we read through
the title and abstract and also verified whether the WBCD and ML
classification were the focus of the papers by going through the
first 11 papers. From the 11 papers, five were excluded. From these
five, three papers were excluded because the WBCD was not the
focus of the paper; rather, a different Wisconsin BC dataset formed
the basis of the research. The remaining two papers were already
included in Yue et al.’s19 work. Therefore, six papers were includ-
ed in this study: three for 2016 and another three for 2017.36-41
The 2018 search produced 5650 papers. Three sample papers
were briefly read to verify selection. Two papers were excluded;
one of the papers was based on unsupervised ML and the other was
based on a different Wisconsin BC dataset. We included one of the
papers from this search. In addition, the WBCD was also part of
the focus of Li and Chen’s30 paper from the search for objective 2
above, and was automatically included here. This resulted in the
inclusion of two papers for 2018.30,42 The 2019 search yield 2900
papers. We went through a sample of seven papers. From these
seven, five were excluded because they were based on a different
Wisconsin BC dataset. The 2019 selection therefore included two
papers.34,43
Study characteristics
For objective 1 
In order to determine the global trend of publications in terms
of country, the PubMed database was searched to determine the
number of publications that the 195 countries contributed towards.
The top ten countries are reported in Figure 2. The top ten first
authors and journals in the field of BC prediction using ML are
shown in Figures 3 and 4. The VOSviewer software identified two
clusters (the red and green cluster) for collaboration amongst the
nine institutions as seen in Figure 5. This means that research col-
laborations occurred between any two institutions belonging to the
same cluster. The institutions depicted per cluster in Figure 5 are
listed in Supplementary Table 4. The VOSviewer software found
14 clusters (depicted by the different colours) for co-occurrence of
the 123 author keywords shown in Figure 6. Co-occurrence of the
keywords exists between any two keywords within the same clus-
ter. The keywords per cluster from Figure 6 are listed in
Supplementary Table 5.      
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Figure 1. PRISMA 2009 flow diagram used for the screening and
selection of breast cancer (BC) prediction studies focused on the
use of machine learning and BC blood analysis data (the BC
Coimbra Dataset [BCCD]). (http://prisma-statement.org/PRISMA
Statement/FlowDiagram).
Figure 2. Top ten publishing countries for breast cancer predic-
tion using machine learning publications, 2015-2019.
Figure 3. Top ten first authors for publications focused on breast
cancer prediction using machine learning from 2015 to 2019.  










For objectives 2 and 3
The accuracy summary measure was most often used (n = 15)
by authors to report model results from the 19 distinct studies
(Table 1). The top three studies with the highest model accuracy
for the BCCD were: Hernández-Julio et al.34 (accuracy = 95.90%),
Singh26 (accuracy = 92.11%) and Polat and Senturk27 (accuracy =
91.37%). The following studies achieved highest accuracy for the
WBCD: Abdar and Makarenkov43 (accuracy = 100%), Elgedawy41
(accuracy = 99.42 %) and Hernández-Julio et al.34 (accuracy =
99.40%).
The AUC was the second most commonly used summary mea-
sure. Patrício et al.’s20 study had the best ranking AUC ([87, 91]
95% confidence interval) for the BCCD and the study by Bazazeh
and Shubair37 had the highest AUC (99.90%) for the WBCD.
Finally, only Hung et al.’s25 study reported the F1 score (82%)
which was for the BCCD.
Discussion
Summary of evidence
For objective 1 
Analysis by country
In total, 86 of the 195 countries were represented across the
five-year analysis, with the top ten publishing countries depicted in
Figure 2. The United States of America (USA) produced the most
publications (n = 803), which amounts to roughly 27% of the 2928
total global publications produced during this period. China ranked
second with 394 publications (approximately 13% of the 2928
publications). These top two country rankings in our study are
unsurprising because a similar trend is noted in their Research and
Development (R&D) expenditure. The USA invests the most
($476,452.0M in Purchasing Power Parity Dollars [PPP$]; 71.5%
spent by the business sector) on R&D.44 China ranks second in
R&D investment ($370,605.5M in PPP$; 77.3% spent by the busi-
ness sector).44 In addition, nine of the top ten countries (all besides
Sweden) are ranked in the top 15 R&D spenders.44 Specifically,
strong spending from the business sector is a key factor in the suc-
cess of R&D amongst these top countries.44
Among the top five publishing countries shown in Figure 2,
only one (China) was a BRICS member country. BRICS is the
association of five (Brazil, Russia, India, China and South Africa)
emerging economies. China’s good performance is consistent with
the finding from a previous study that found BC to be one of the
priority diseases and popular research topics in China in recent
years.45 This may be attributed to the Chinese healthcare reforms
within the healthcare field which started in the 1980s and the coun-
try having gone through three reform periods.46 For more on
Chinese healthcare reform, refer to Yip et al.47 and Chen.48
With the exception of China, the remaining nine of the top ten
countries were developed countries. This is despite BC being a
global burden.6 However, this finding is expected because devel-
oping countries spend comparatively less money on R&D due to
limited resources.44
Analysis by first author
Approximately 2419 distinct first authors contributed towards
the 2928 papers published within this five-year analysis. In addi-
tion, roughly 99% of all first authors produced five or less papers.
The top ten first authors are shown in Figure 3.  
Analysis by journal
The 2928 publications in the study period were published in
670 journals. From these 670 journals, the majority of the publica-
tions were primarily from specialty journals focused on cancer or
BC, as seen in Figure 4. From the top ten, only PLoS One (ranked
second) is a general journal. Breast Cancer Research and
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Figure 4. Top ten journals that breast cancer prediction using
machine learning publications were most commonly published in
during the period of 2015-2019. 
Figure 5. Institutional collaboration network of breast cancer prediction using machine learning-related publications, 2015-2019. The
size of the nodes indicates the number of collaborative publications. The higher the number of collaborative publications, the larger
the size of the node and vice versa. The distance between two nodes is inversely proportional to the number of collaborations between
two institutions. This implies that shorter distances indicate more collaboration between the institutions. There are two clusters: the
red and green clusters.









Treatment was the journal with the highest number of publications
(n = 173; 6%), with an impact factor of 3.471. All top ten journals
are peer reviewed and their average impact factor is 3.337.   
Analysis of institutional collaborations
The institutional collaborations network is shown in Figure 5
and listed in Supplementary Table 4. Research collaborations
occurred between any two institutions within the same cluster. The
Cancer Prevention Institute of California from the USA, the
Memorial Sloan Kettering Cancer Centre from the USA and the
Department of Epidemiology, Harvard T.H. Chan School of Public
Health from the USA were the top three influential institutions in
this study period. From the nine institutions, seven (77%) were
from the USA. Internationally, the USA collaborates only with
Canada and Germany. These three countries are also amongst the
top five publishing countries (Figure 2). This shows that research
in this field is lacking in developing countries since there was no
developing country represented in the top ten publication countries
(Figure 2). In addition, no developing country was listed in collab-
orative research with institutions from the developed countries
(Supplementary Table 4). This finding is consistent with a previous
finding, which noted that the history of general research collabora-
tions between developed and developing countries is not illustri-
ous.49 In the future, regulations should be put into place to encour-
age international collaborations between developed and develop-
ing countries. This will allow for sharing of valuable expertise and
resources with developing countries, which will also consequently
increase the latter’s research output. Finally, China’s good perfor-
mance could steer collaboration with the other BRICS members. 
Analysis of co-occurrence of author keywords
The author keyword analysis is shown in Figure 6 and listed in
Supplementary Table 5. The analysis shows that the top ten most
prominent topics in this field are: mammography, screening, epi-
demiology, prognosis, mammographic density, chemotherapy,
Machine Learning, neoadjuvant chemotherapy, magnetic reso-
nance imaging and risk factors. Broadly, this shows that authors
are most interested in BC screening and detection methods and
understanding the underlying determinants of the BC disease using
the ML paradigm. We also manually identified ML-related key-
words shown in bold in Supplementary Table 5. Most of the ML-
related keywords are confined in Cluster 4, indicating that these
keywords appear frequently together. As expected, and generally
known in the medical field, classification appears to be the most
frequent ML-related paradigm used in the studies. In addition,
Neural Networks, Deep Learning, Support Vector Machine and
Logistic Regression (Cluster 2) are the common ML algorithms
used in this field.   
For objective 2
It is noteworthy to mention that the top two studies in terms of
accuracy for BCCD, as seen in Table 1, adopted some form of fea-
ture selection for their ML models. This means that instead of
using all the BCCD features, the authors first used some form of
ML-related technique to identify the most important BCCD fea-
tures and used this subset of features to build their models. Feature
selection is important because it assists with improved ML model
performance.50
Hernández-Julio et al.34 proposed a novel framework based on
clusters and pivot tables using the MATLAB software. As shown
in Table 1, these authors achieved the highest accuracy (95.90%)
with the 10-fold Cross-Validation (CV) sampling strategy. This
was achieved with the model they created using their framework
and the following BCCD features: BMI, Glucose, Leptin, Resistin
and MCP-1. Singh’s26 K-Nearest Neighbors (K-NN) model
attained second position with an accuracy of 92.11% where 67% of
the BCCD was used for training and 33% of the data was used for
testing the model. In contrast to Hernández-Julio et al.’s34 finding,
Singh26 identified and used a different subset of features from the
BCCD (Glucose, Resistin and Age) to build the model. Similar to
Hernández-Julio et al.,34 Singh26 also used MATLAB for model-
building. It is unclear whether Polat and Senturk27 used feature
selection. Nevertheless, the authors obtained a hybrid Adaptive
Boosting (AdaBoost) model together with 10-fold CV that
achieved 91.37% accuracy. 
These two different subsets of BCCD features found in the two
studies above may have important real-world implications as they
could potentially identify new and cheaper BC biomarkers.
However, clinical validations would be required as complementary
analyses. To accomplish this, the results from the studies need to
be presented to clinicians; however, it is unfortunate that this step
appears to be lacking in these studies.    
In contrast to the findings from objective 1 above, it is interest-
ing to note that the first author (Singh26), ranked in the top three
BCCD studies for the accuracy measure (Table 1), was from a dif-
ferent BRICS country (India). However, this is consistent with the
finding that India has research potential since the country appears
in the top 15 R&D spenders (rank = 7th).44 India spends approxi-
mately $48,063.0M in PPP$ with 35.5% of their business sector
contributing towards R&D.44
For objective 3
Abdar and Makarenkov’s43 ensemble model achieved the high-
est accuracy (100%) using the WBCD, as shown in Table 1. The
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Figure 6. Author keywords co-occurrence network of breast can-
cer prediction using machine learning-related publications from
2015 to 2019. The size of the nodes depicts the frequency of the
keywords, so, the larger the node, the higher the frequency and
vice versa. The distance between two nodes is inversely propor-
tional to the number of co-occurrence between the keywords.
This means that shorter distances indicate greater co-occurrence
between the keywords. There are 14 clusters, each represented by










WBCD was split into 50% for training and 50% for testing and the
16 missing rows were first removed. Although this model appears
to have obtained excellent results, this may be unreliable since no
CV approach was used to handle any bias in this small dataset.
Elgedawy’s41 Random Forest (RF) model ranked second in accu-
racy (99.42%) for the WBCD. The data allocation was 75% for
training and 25% for testing. This model used a subset of the
WBCD features (Cell Size, Cell Shape, Clump Thickness and Bare
Nuclei) which was first identified by the authors. As with Abdar’s
and Makarenkov’s43 study, Elgedawy41 should have used some
form of CV to handle the bias in the dataset. In contrast to
Elgedawy,41 Hernández-Julio et al.34 identified the following
important WBCD features: Uniformity of Cell Size, Marginal
Adhesion, Single Epithelial Cell Size, Bare Nuclei and Normal
Nucleoli. Using these features, Hernández-Julio et al.’s34 model
ranked in third position with an accuracy of 99.40% by 10-fold CV
which was created with the MATLAB software. The important fea-
tures found in the two studies could potentially be BC biomarkers.
However, similar to the findings in objective 2, none of these stud-
ies seemed to have any clinical validations. Finally, it is unsurpris-
ing that the authors (Abdar and Makarenkov43) with the highest
WBCD accuracy was from Canada since Canada was also found to
appear in the top ten publishing countries in the results for objec-
tive 1.    
Comparison of breast cancer prediction results amongst the tra-
ditional breast cancer screening and or detection methods and
the machine learning-based results from objectives 2 and 3 
The different BC screening and detection methods that are
used globally, have varied accuracy levels. The traditional BC
screening method of BSE in developing countries has an estimated
accuracy of between 20% and 30%.51 The CBE method is also
commonly used to screen patients for BC in developing countries
and this method has roughly 54% accuracy.52 In developed coun-
tries, the mammography approach used for screening BC in
patients, achieves an estimated 89.3% accuracy.53 The triple
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Table 1. Summary list of studies focused on BC prediction using ML classification with the BCCD and the WBCD. The contents of
this table are ordered first by dataset, and then by summary measure, from highest to lowest. Boldface denotes the highest result per
dataset and summary measure.
Reference                        Dataset                 Country*                        Sampling strategy       ML Algorithm                     Summary measure 
                                                                                                                                                                                                  (in %)
Hernández-Julio et al.34           BCCD                            Colombia                                  10-fold CV                              clusters + pivot table                  95.90 (Accuracy)
Singh26                                         BCCD                            India                                          67-33 training-testing          K-NN                                                92.11 (Accuracy)
Polat and Senturk27                   BCCD                            Turkey                                       10-fold CV                              AdaBoost                                        91.37 (Accuracy)
Akben28                                        BCCD                            Turkey                                       10-fold CV                              DT                                                    90.52 (Accuracy)
Islam and Poly35                         BCCD                            Taiwan (China)                       10-fold CV                              K-NN                                                86.00 (Accuracy)
Araújo et al.33                             BCCD                            Brazil                                         70-30 training-testing          NN                                                    80.67 (Accuracy)
                                                                                                                                                10-fold CV                              
Aslan et al.31                               BCCD                            Turkey                                       80-20 training-testing          ELM                                                 80.00 (Accuracy)
Livieris32                                     BCCD                            Greece                                      10-fold CV                              K-NN                                                62.00 (Accuracy)
Patrício et al.20                           BCCD                            Portugal                                    MCCV                                      SVM                                                 87.00, 91.00]
                                                                                                                                                                                                                                                           (95% CI for AUC)
Li and Chen30                              BCCD                            United Kingdom                     70-30 training-testing          RF                                                     78.50 (AUC)
Hung et al.25                                BCCD                            Vietnam                                    80-20 training-testing          DT                                                    82.00 (F1 score)
Abdar and Makarenkov43          WBCD                           Canada                                      50-50 training-testing          CWV-BANN-SVM                           100.00 (Accuracy)
                                                                                                                                                                                                 (an ensemble of 
                                                                                                                                                                                                 ANN + SVM)                                  
Elgedawy41                                  WBCD                           Saudi Arabia                             75-25 training-testing          RF                                                     99.42 (Accuracy)
Hernández-Julio et al.34           WBCD                           Colombia                                  10-fold CV                              Clusters + pivot table                 99.40 (Accuracy)
Chaurasia et al.42                      WBCD                           India                                          Stratified 10-fold CV            NB                                                    97.36 (Accuracy)
Asri et al.36                                  WBCD                           Morocco                                   10-fold CV                              SVM                                                 97.13 (Accuracy)
Alzubaidi et al.38                        WBCD                           United Kingdom                     LOOCV                                   SVM                                                 97.00 (Accuracy)
                                                                                                                                                                                                 (quadratic-linear kernel)           97.00 (Accuracy)
                                                                                                                                                                                                 K-NN (Minkowsky and 
                                                                                                                                                                                                 Euclidean distance measures)
Islam et al.40                               WBCD                           Bangladesh                              10-fold CV                              SVM                                                 97.00 (Accuracy)
Chaurasia and Pal39                   WBCD                           India                                          10-fold CV                              SMO (SVM)                                   96.20 (Accuracy)
Bazazeh and Shubair37             WBCD                           United Arab Emirates           10-fold CV                              RF                                                     99.90
                                                                                                                                                                                                                                                           (AUC)
Li and Chen30                              WBCD                           United Kingdom                     70-30 training-testing          RF                                                     98.90 (AUC)
*Country is based on the first author’s affiliation. BC, breast cancer; ML, machine learning; WBCD, Wisconsin breast cancer dataset; BCCD, Breast Cancer Coimbra dataset; CV, cross-validation; SVM, support vector
machine; RF, random forest; AUC, area under the receiver operating characteristics curve; LOOCV, leave-one-out cross-validation; K-NN, K-nearest neighbors; SMO, sequential minimal optimization; NB, naïve Bayes;
MCCV, Monte Carlo cross validation; CI, confidence interval; AdaBoost, adaptive boosting; ELM, extreme learning machine; DT, decision tree; NN, Neural Network; CWV-BANN-SVM, confidence-weighted voting-boosting
artificial neural network-support vector machine.










assessment test that is currently used worldwide for BC detection,
is known to provide an accuracy of approximately 99%.5 In con-
trast to the aforementioned methods, as seen in Table 1, in the best
case scenario, the ML-based method was able to achieve 100%
accuracy in the prediction of BC. This depicts the usefulness of the
ML-based approach and shows that ML has potential in identifying
BC in patients, to a degree where it could exceed the accuracy of
the traditional approaches used for the same purpose.  
Limitations and future directions
For objective 1 
The use of only PubMed as a source for retrieving publication
data was a limitation. In future, researchers could work on a bib-
liometric study focused on BC prediction using ML by searching
PubMed, Scopus and Web of Science online databases. Secondly,
the five-year restriction in the search was a limitation. In the future,
researchers could broaden this to a ten-year analysis. Thirdly, since
some papers may not have assigned author keywords, some of the
topics may be underrepresented in this study. Further analysis
could include both author and Medical Subject Headings (MeSH)
keywords.  
For objective 2 
The inclusion criteria were restricted to studies focused on ML
classification only for the BCCD. In the future, reviews should
include other ML paradigms used with the BCCD, such as semi-
supervised ML. In addition, any BCCD papers using ML published
after this study could form the inclusion in future reviews. 
For objective 3 
The small sample size (n = 3 for 2016 and 2017; n = 2 for 2018
and 2019) was the main limitation for the WBCD papers, since the
objective of this study was to only provide a brief overview of the
WBCD. In future, this sample size could increase and also cover
newly published papers showing good performance for the WBCD.
Only ML classification studies were included in the present study. In
future, researchers could expand this to also include WBCD studies
focused on other ML approaches such as unsupervised ML.  
Finally, we were not able to include papers that were not writ-
ten in English and this may therefore have introduced a language
bias. In the future, researchers could hire an interpreter to aid with
interpretation of non-English papers and include these into future
reviews.   
Conclusions
A bibliometric analysis of BC prediction using ML publica-
tions was carried out for the past five years by searching PubMed.
The USA was the most influential country, with the highest num-
ber of publications, and 2419 distinct first authors contributed
towards the 2928 papers found in this period. Breast Cancer
Research and Treatment was the highest ranked journal, with an
impact factor of 3.471. Institutional collaborations appear to main-
ly occur within the USA. The Cancer Prevention Institute of
California from the USA had the highest number of collaborative
publications. No developing country was listed in both the top ten
publishing countries and institutional collaborations. The most
researched topics in this field are the utilization of ML for BC
screening, detection and understanding the determinants of the dis-
ease. This paper reviewed studies published on using a blood anal-
ysis dataset, the BCCD, with ML for BC prediction. The top two
authors used some form of feature selection in their ML models.
Body Mass Index, Glucose, Leptin, Resistin and MCP-1 were
found to be the best BCCD features in one study. Another study
found Glucose, Resistin and Age to be the most optimal BCCD
features. These two sets of blood tests may potentially identify new
BC biomarkers; however, none of the authors presented their
results to clinicians to perform clinical validations. 
This paper also provided a brief overview of studies published
on BC prediction using a FNAC biopsy WBCD dataset and ML.
Although the highest ranked author achieved 100% model perfor-
mance, these results were unreliable due to no approach being used
to handle any bias in the dataset. Two of the top three ranked stud-
ies used feature selection in their models. One study found Cell
Size, Cell Shape, Clump Thickness and Bare Nuclei to be the best
WBCD features. Another study identified Uniformity of Cell Size,
Marginal Adhesion, Single Epithelial Cell Size, Bare Nuclei and
Normal Nucleoli as the most optimal WBCD features. However,
similar to the BCCD finding, these results were not shown to clin-
icians to validate whether these may potentially be BC biomarkers.
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